icad's EPS (Basic) for the
three
months ended in Mar. 2024 was $-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.12.
icad's EPS without NRI for the
three
months ended in Mar. 2024 was $-0.05.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.19.
During the past 3 years, the average EPS without NRIGrowth Rate was 30.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 15.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 0.30% per year.
During the past 13 years, icad's highest 3-Year average EPS without NRI Growth Rate was 56.50% per year. The lowest was -96.60% per year. And the median was 7.70% per year.
icad Earnings per Share (Diluted) Historical Data
The historical data trend for icad's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of icad's Earnings per Share (Diluted)
For the Medical Devices subindustry, icad's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
icad's PE Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, icad's PE Ratio distribution charts can be found below:
* The bar in red indicates where icad's PE Ratio falls into.
icad Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
icad's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
icad (NAS:ICAD) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
icad Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of icad's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICAD has been successfully added to your 